Literature DB >> 31518877

Metformin inhibited Nod-like receptor protein 3 inflammasomes activation and suppressed diabetes-accelerated atherosclerosis in apoE-/- mice.

Ge Tang1, Fengqi Duan1, Weixuan Li1, Yiqin Wang1, Cheng Zeng1, Jia Hu1, Hongyu Li2, Xuanhong Zhang2, Yanming Chen3, Hongmei Tan4.   

Abstract

AIMS: The present study aimed to investigate the effect of metformin on diabetes-accelerated atherosclerosis and whether Nod-like receptor protein 3 (NLRP3) inflammasome is a target for metformin.
MATERIALS AND METHODS: ApoE-/- male mice were divided randomly into control, streptozocin-induced diabetes mellitus and metformin groups. Metabolic parameters, atherosclerotic lesion, activation of NLRP3 inflammasomes and related signaling pathways were detected. THP-1-differentiated macrophages were used in in vitro experiments.
RESULTS: Compared with control mice, increased plasma lipids and proinflammatory interleukin-1β, aggravated macrophage infiltration into the atherosclerotic lesion, and accelerated development of atherosclerosis were observed in diabetic mice, which were associated with the activation of NLRP3 inflammasomes and dysregulation of thioredoxin-1 and thioredoxin-interacting protein. Treatment with metformin alleviated diabetes-induced metabolic disorders and atherosclerosis, as well as NLRP3 inflammasomes activation and dysregulation of thioredoxin-1/thioredoxin-interacting protein. In vitro experiments showed that high glucose induced the accumulation of reactive oxygen species and activated NLRP3 inflammasomes, which was significantly suppressed by treatment with metformin or antioxidant N-acetyl-L-cysteine. Moreover, Compound C, an inhibitor of adenosine 5'-monophosphate-activated protein kinase (AMPK), blocked the anti-inflammatory effect of metformin, indicating that metformin inhibited high glucose-induced NLRP3 inflammasomes activation through AMPK activation. Moreover, high glucose decreased thioredoxin-1 expression and increased thioredoxin-interacting protein expression, which was also reversed by metformin.
CONCLUSIONS: Metformin inhibited NLRP3 inflammasomes activation and suppressed diabetes-accelerated atherosclerosis in apoE-/- mice, which at least partially through activation of AMPK and regulation of thioredoxin-1/thioredoxin-interacting protein.
Copyright © 2019 The Authors. Published by Elsevier Masson SAS.. All rights reserved.

Entities:  

Keywords:  Atherosclerosis; Metformin; NLRP3 inflammasomes

Mesh:

Substances:

Year:  2019        PMID: 31518877     DOI: 10.1016/j.biopha.2019.109410

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  18 in total

Review 1.  Metabolic Dysfunction in the Regulation of the NLRP3 Inflammasome Activation: A Potential Target for Diabetic Nephropathy.

Authors:  Wenli Zhao; Le Zhou; Petr Novák; Xian Shi; Chuang Biao Lin; Xiao Zhu; Kai Yin
Journal:  J Diabetes Res       Date:  2022-06-09       Impact factor: 4.061

Review 2.  The NLRP3 Inflammasome Pathway: A Review of Mechanisms and Inhibitors for the Treatment of Inflammatory Diseases.

Authors:  Hallie M Blevins; Yiming Xu; Savannah Biby; Shijun Zhang
Journal:  Front Aging Neurosci       Date:  2022-06-10       Impact factor: 5.702

Review 3.  Diabetes Mellitus Promotes the Development of Atherosclerosis: The Role of NLRP3.

Authors:  Jingxue Ye; Lanfang Li; Min Wang; Qiuxiao Ma; Yu Tian; Qiong Zhang; Jiushi Liu; Bin Li; Bengang Zhang; Haitao Liu; Guibo Sun
Journal:  Front Immunol       Date:  2022-06-29       Impact factor: 8.786

Review 4.  How to Restore Oxidative Balance That Was Disrupted by SARS-CoV-2 Infection.

Authors:  Kajetan Kiełbowski; Mariola Herian; Andrzej Pawlik
Journal:  Int J Mol Sci       Date:  2022-06-07       Impact factor: 6.208

5.  Whole-transcriptome Analysis of Fully Viable Energy Efficient Glycolytic-null Cancer Cells Established by Double Genetic Knockout of Lactate Dehydrogenase A/B or Glucose-6-Phosphate Isomerase.

Authors:  Elizabeth Mazzio; Ramesh Badisa; Nzinga Mack; Shamir Cassim; Masa Zdralevic; Jacques Pouyssegur; Karam F A Soliman
Journal:  Cancer Genomics Proteomics       Date:  2020 Sep-Oct       Impact factor: 4.069

Review 6.  Evaluation of hypoglycemic therapeutics and nutritional supplementation for type 2 diabetes mellitus management: An insight on molecular approaches.

Authors:  Murugan Prasathkumar; Robert Becky; Salim Anisha; Chenthamara Dhrisya; Subramaniam Sadhasivam
Journal:  Biotechnol Lett       Date:  2022-02-04       Impact factor: 2.461

Review 7.  NLRP3 Inflammasome: A Potential Alternative Therapy Target for Atherosclerosis.

Authors:  Yang Liu; Chao Li; Honglin Yin; Xinrong Zhang; Yunlun Li
Journal:  Evid Based Complement Alternat Med       Date:  2020-03-31       Impact factor: 2.629

8.  Identification of Potential Key Genes Involved in the Carotid Atherosclerosis.

Authors:  Youshi Meng; Chunli Zhang; Lucong Liang; Lei Wei; Hao Wang; Fengkun Zhou; Rongjie Li; Donghua Zou; Xiaohua Huang; Jie Liu
Journal:  Clin Interv Aging       Date:  2021-06-10       Impact factor: 4.458

Review 9.  Role of Thioredoxin-Interacting Protein in Diseases and Its Therapeutic Outlook.

Authors:  Naila Qayyum; Muhammad Haseeb; Moon Suk Kim; Sangdun Choi
Journal:  Int J Mol Sci       Date:  2021-03-09       Impact factor: 5.923

Review 10.  NLRP3 Inflammasome in Inflammation and Metabolism: Identifying Novel Roles in Postburn Adipose Dysfunction.

Authors:  Roohi Vinaik; Dalia Barayan; Marc G Jeschke
Journal:  Endocrinology       Date:  2020-09-01       Impact factor: 4.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.